Upstream Bio
UPB
Upstream Bio (UPB) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Neutral | $9.00 from $8.00 | Aug 14, 2026 |
| Truist Securities | Maintained | Buy | $25.00 from $43.00 | Aug 12, 2026 |
| JP Morgan | Downgraded | Overweight → Neutral | $8.00 from $35.00 | Jun 12, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $36.00 | Jun 3, 2026 |
| Mizuho | Maintained | Outperform | $50.00 from $51.00 | May 14, 2026 |
| Evercore ISI Group | Downgraded | Outperform → In-Line | $15.00 from $40.00 | Mar 27, 2026 |
| Mizuho | Initiated Coverage | Outperform | $51.00 | Dec 18, 2025 |
| LifeSci Capital | Initiated Coverage | Outperform | $43.00 | Dec 2, 2025 |
| Evercore ISI Group | Initiated Coverage | Outperform | $40.00 | Nov 18, 2025 |
| Truist Securities | Initiated Coverage | Buy | $47.00 | Oct 14, 2025 |
| William Blair | Initiated Coverage | Outperform | — | Nov 5, 2024 |
| Piper Sandler | Initiated Coverage | Overweight | $75.00 | Nov 5, 2024 |
| TD Cowen | Initiated Coverage | Buy | — | Nov 5, 2024 |
| JP Morgan | Initiated Coverage | Overweight | $38.00 | Nov 5, 2024 |
Frequently asked questions
What is the latest analyst rating on UPB?
On Aug 14, 2026, JP Morgan maintained Upstream Bio at Neutral with a price target of $9.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.